Cost of Revenue: Key Insights for Takeda Pharmaceutical Company Limited and MorphoSys AG

Pharma Giants: Cost of Revenue Trends Unveiled

__timestampMorphoSys AGTakeda Pharmaceutical Company Limited
Wednesday, January 1, 201477000520990000000
Thursday, January 1, 201577000535405000000
Friday, January 1, 201697000558755000000
Sunday, January 1, 201733000495921000000
Monday, January 1, 20181796629659690000000
Tuesday, January 1, 2019120851981089764000000
Wednesday, January 1, 20209174146994308000000
Friday, January 1, 2021322000001106846000000
Saturday, January 1, 2022486200001244072000000
Sunday, January 1, 2023583550001431505000000
Monday, January 1, 20241431505000000
Loading chart...

Unlocking the unknown

Cost of Revenue: A Comparative Analysis

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for strategic planning. This analysis delves into the cost of revenue for Takeda Pharmaceutical Company Limited and MorphoSys AG from 2014 to 2023. Takeda, a global leader, consistently shows a robust cost of revenue, peaking at approximately 1.43 trillion in 2023, reflecting a 174% increase since 2014. In contrast, MorphoSys AG, a smaller biotech firm, exhibits a more volatile trend, with costs rising from a modest 77,000 in 2014 to 58 million in 2023, marking a staggering 75,000% increase. This disparity highlights the scale and operational differences between the two companies. Notably, the data for 2024 is incomplete, indicating potential shifts in the coming years. Such insights are invaluable for investors and stakeholders aiming to navigate the complexities of the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025